Literature DB >> 25708356

Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.

Martina Curto1, Luana Lionetto, Francesco Fazio, Dimos-Dimitrios Mitsikostas, Paolo Martelletti.   

Abstract

Kynurenine pathway, the quantitatively main branch of tryptophan metabolism, has been long been considered a source of nicotinamide adenine dinucleotide, although several of its products, the so-called kynurenines, are endowed with the capacity to activate glutamate receptors, thus potentially influencing a large group of functions in the central nervous system (CNS). Migraine, a largely unknown pathology, is strictly related to the glutamate system in the CNS pathologic terms. Despite the large number of studies conducted on migraine etio-pathology, the kynurenine pathway has been only recently linked to this disease. Nonetheless, some evidence suggests an intriguing role for some kynurenines, and an exploratory study on the serum kynurenine level might be helpful to better understand possible alterations of the kynurenine pathway in patients suffering from migraine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25708356     DOI: 10.1007/s11739-015-1208-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  78 in total

1.  Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice.

Authors:  Francesco Fazio; Cristina Zappulla; Serena Notartomaso; Carla Busceti; Alban Bessede; Pamela Scarselli; Carmine Vacca; Marco Gargaro; Claudia Volpi; Massimo Allegrucci; Luana Lionetto; Maurizio Simmaco; Maria Laura Belladonna; Ferdinando Nicoletti; Francesca Fallarino
Journal:  Neuropharmacology       Date:  2014-02-21       Impact factor: 5.250

2.  3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction.

Authors:  L E Goldstein; M C Leopold; X Huang; C S Atwood; A J Saunders; M Hartshorn; J T Lim; K Y Faget; J A Muffat; R C Scarpa; L T Chylack; E F Bowden; R E Tanzi; A I Bush
Journal:  Biochemistry       Date:  2000-06-20       Impact factor: 3.162

3.  On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress.

Authors:  R Lugo-Huitrón; T Blanco-Ayala; P Ugalde-Muñiz; P Carrillo-Mora; J Pedraza-Chaverrí; D Silva-Adaya; P D Maldonado; I Torres; E Pinzón; E Ortiz-Islas; T López; E García; B Pineda; M Torres-Ramos; A Santamaría; V Pérez-De La Cruz
Journal:  Neurotoxicol Teratol       Date:  2011-07-13       Impact factor: 3.763

4.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 5.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

6.  Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients.

Authors:  P Martelletti; G Stirparo; S Morrone; C Rinaldi; M Giacovazzo
Journal:  J Mol Med (Berl)       Date:  1997-06       Impact factor: 4.599

7.  Immunological aspects in migraine: increase of IL-10 plasma levels during attack.

Authors:  I Munno; M Marinaro; A Bassi; M A Cassiano; V Causarano; V Centonze
Journal:  Headache       Date:  2001-09       Impact factor: 5.887

8.  Kynurenic acid inhibits glutamatergic transmission to CA1 pyramidal neurons via α7 nAChR-dependent and -independent mechanisms.

Authors:  Jyotirmoy Banerjee; Manickavasagom Alkondon; Edson X Albuquerque
Journal:  Biochem Pharmacol       Date:  2012-08-02       Impact factor: 5.858

9.  Pharmacogenetic insights into migraine treatment in children.

Authors:  Giovanna Gentile; Lorenza Chiossi; Luana Lionetto; Paolo Martelletti; Marina Borro
Journal:  Pharmacogenomics       Date:  2014-08       Impact factor: 2.533

10.  Xanthurenic acid distribution, transport, accumulation and release in the rat brain.

Authors:  Serge Gobaille; Véronique Kemmel; Daniel Brumaru; Christophe Dugave; Dominique Aunis; Michel Maitre
Journal:  J Neurochem       Date:  2008-01-07       Impact factor: 5.372

View more
  12 in total

1.  O066. Kynurenine pathway metabolites in cluster headache.

Authors:  Martina Curto; Luana Lionetto; Matilde Capi; Andrea Negro; Lidia D'Alonzo; Ferdinando Nicoletti; Paolo Martelletti
Journal:  J Headache Pain       Date:  2015-12       Impact factor: 7.277

2.  Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72).

Authors:  M Lukács; K Warfvinge; J Tajti; F Fülöp; J Toldi; L Vécsei; L Edvinsson
Journal:  J Headache Pain       Date:  2017-03-23       Impact factor: 7.277

3.  Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.

Authors:  Kristian Agmund Haanes; Lars Edvinsson
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

4.  The association between dietary tryptophan intake and migraine.

Authors:  Soodeh Razeghi Jahromi; Mansoureh Togha; Zeinab Ghorbani; Azita Hekmatdoost; Faezeh Khorsha; Pegah Rafiee; Pedram Shirani; Morvarid Nourmohammadi; Hossein Ansari
Journal:  Neurol Sci       Date:  2019-06-28       Impact factor: 3.307

Review 5.  An Emerging Cross-Species Marker for Organismal Health: Tryptophan-Kynurenine Pathway.

Authors:  Laiba Jamshed; Amrita Debnath; Shanza Jamshed; Jade V Wish; Jason C Raine; Gregg T Tomy; Philippe J Thomas; Alison C Holloway
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

Review 6.  Anti-CGRP monoclonal antibodies in migraine: current perspectives.

Authors:  Maria Adele Giamberardino; Giannapia Affaitati; Martina Curto; Andrea Negro; Raffaele Costantini; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2016-06-23       Impact factor: 3.397

7.  Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion.

Authors:  A Csáti; L Edvinsson; L Vécsei; J Toldi; F Fülöp; J Tajti; K Warfvinge
Journal:  J Headache Pain       Date:  2015-12-01       Impact factor: 7.277

Review 8.  Genetic and biochemical changes of the serotonergic system in migraine pathobiology.

Authors:  Claudia Francesca Gasparini; Robert Anthony Smith; Lyn Robyn Griffiths
Journal:  J Headache Pain       Date:  2017-02-13       Impact factor: 7.277

9.  Altered serum levels of kynurenine metabolites in patients affected by cluster headache.

Authors:  Martina Curto; Luana Lionetto; Andrea Negro; Matilde Capi; Francesca Perugino; Francesco Fazio; Maria Adele Giamberardino; Maurizio Simmaco; Ferdinando Nicoletti; Paolo Martelletti
Journal:  J Headache Pain       Date:  2016-03-22       Impact factor: 7.277

10.  KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion.

Authors:  M Lukács; K Warfvinge; L S Kruse; J Tajti; F Fülöp; J Toldi; L Vécsei; L Edvinsson
Journal:  J Headache Pain       Date:  2016-07-05       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.